<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>One hundred and eighty-seven patients with different stages of <z:e sem="disease" ids="C0241832" disease_type="Disease or Syndrome" abbrv="">cerebrovascular insufficiency</z:e> (CI) have been examined </plain></SENT>
<SENT sid="1" pm="."><plain>A diagnosis of CI was based on the results of neurological and neuropsychological study, ultrasonic dopplerography, rheo- and encephalography, electrocardiography, brain MRI and eyegrounds examination </plain></SENT>
<SENT sid="2" pm="."><plain>Neurological scales were used for neurological status assessment and further data processing </plain></SENT>
<SENT sid="3" pm="."><plain>The study aimed at evaluation of tolerability and clinical efficacy of the medication and complications in CI course </plain></SENT>
<SENT sid="4" pm="."><plain>Semax treatment resulted in significant clinical improvement, stabilization of the disease progress and reduced a risk of <z:hpo ids='HP_0001297'>stroke</z:hpo> and transitory ischemic attacks in the disease course </plain></SENT>
<SENT sid="5" pm="."><plain>The drug is featured by minor percent of side-effects and is well tolerated by patients, including those of older age groups </plain></SENT>
</text></document>